FDA moves to block some compounded GLP-1s

GLP-1 compounding just got squeezed again. The FDA did not ban every compounded weight-loss shot on the market, but it took a big step toward shutting down the large-scale version of that business. On April 30, 2026, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list that can let outsourcing facilities compound drugs from bulk ingredients. ### What changed this week? The new move is about 503B outsourcing facilities — the bigger compounders that can make office-stock drugs in bulk. The FDA said these three GLP-1 ingredients should not stay on the 503B bulks list because it does not see a clinical need for outsourcing facilities to compound them from bulk substances. It also opened a public comment period that runs through June 29, 2026, before making the decision final. ### Why does the bulks list matter? Because this is one of the main legal doors compounders use. Under federal law, 503B facilities usually cannot compound from bulk drug substances unless the ingredient is on that bulks list or the finished drug is on the FDA shortage list at the time of compounding, distribution, and dispensing. If the FDA closes this door, mass-produced compounded GLP-1 supply gets much harder to justify. ### Didn’t shortages already end? Yes — and that is the real backdrop here. The FDA said semaglutide injection shortages were resolved on February 21, 2025. Tirzepatide had already been removed from the shortage list on October 2, 2024, then reevaluated, with the agency again concluding the shortage was resolved. Once an approved drug is no longer in shortage, the shortage exception for compounding starts to disappear. ### So is all compounding over? Not quite. Traditional 503A pharmacies can still compound for an individual patient with a prescription, but they are not supposed to make drugs that are “essentially copies” of commercially available products in regular or inordinate amounts. The FDA’s April 1 update made clear that even a semaglutide mix with something like substitutable. ### Why are telehealth companies in the blast zone? Because the FDA has been attacking the marketing side too. On March 3, 2026, the agency announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products sold on their websites. So this is not one isolated policy tweak — it is part of a broader campaign against the way compounded GLP-1s have been advertised and distributed online. ### What does this mean for patients? The cheap, easy version of access is what is really at risk. During the shortage era, compounded semaglutide and tirzepatide spread through telehealth clinics and med spas because branded products were hard to find and often cost far more. If 503B bulk compounding gets boxed out. That likely means higher out-of-pocket costs, more scrutiny, and fewer “customized” GLP-1 offers that are really just substitutes for Wegovy, Ozempic, Zepbound, or Mounjaro. ### What is the real bottom line? Basically, the FDA is trying to end the emergency-era workaround without saying “compounding is illegal” across the board. The agency is narrowing both routes at once — shortage-based compounding and bulk-based outsourcing compounding. If the April 30 proposal becomes final, the parallel weight-loss drug industry.